New Current Report Filed with the SEC Disclosing Receipt of a Notice of Delisting, the Failure to Satisfy a Continued Listing Rule or Standard or the Transfer of a Listing: 8-K – ImmunoCellular Therapeutics, Ltd. (0000822411) (Filer)





A current report on Form 8-K was just filed with the U.S. Securities & Exchange Commission (SEC) disclosing receipt of a notice of delisting, the failure to satisfy a continued listing rule or standard or the transfer of a listing. Details of the current report are:

8-K – ImmunoCellular Therapeutics, Ltd. (0000822411) (Filer)
Filed: 2016-09-01 AccNo: 0001193125-16-699699 Size: 14 KB

Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Filing Date: 2016-09-01T16:47:32-04:00

This is a breaking news story. You can access the complete current report through the SEC’s Edgar system: http://www.sec.gov/Archives/edgar/data/822411/000119312516699699/0001193125-16-699699-index.htm